scholarly journals Central Nervous System Metastases from Ewing''s Sarcoma —Case Report—

1994 ◽  
Vol 34 (11) ◽  
pp. 754-758 ◽  
Author(s):  
Hidekatsu MIZUSHIMA ◽  
Hiroyuki JINBO ◽  
Motohiko SHIMAZU ◽  
Takashi ABE ◽  
Norihiko KUNII ◽  
...  
1989 ◽  
Vol 75 (2) ◽  
pp. 181-182 ◽  
Author(s):  
Gianmaria Bonardi ◽  
Michela Donadio ◽  
Franco Maestroni ◽  
Giuseppe Giaccone ◽  
Alessandro Calciati

Ovarian adenocarcinoma usually disseminates and recurs the abdominal cavity. The detection of central nervous system metastases is rare. In this report we describe a case of intracranial recurrence that developed during a complete local surgical and pathological response and was treated radically with surgery followed by radiation.


2012 ◽  
Vol 2012 ◽  
pp. 1-4 ◽  
Author(s):  
Orit Kaidar-Person ◽  
Jonathan Kuten ◽  
Fadi Atrash ◽  
Salem Billan ◽  
Abraham Kuten

Central nervous system metastases from nasopharyngeal carcinoma (NPC) are uncommon. The patient presented was diagnosed with aggressive advanced NPC resistant to treatment and complicated by a solitary brain metastasis. A PubMed database search was conducted to review the existing literature regarding brain metastases of NPC, using the search terms “nasopharyngeal neoplasia,” “nasopharyngeal carcinoma,” “nasopharynx,” “radiotherapy,” “central nervous system,” and “brain” in section of “Title/Abstract.” The articles were first evaluated by title and then by abstract, and thereafter appropriate manuscripts were evaluated by full text. References of the published papers were also reviewed.


2021 ◽  
pp. 1-6
Author(s):  
Fabricio T Romagnol ◽  
Eliana M Caran ◽  
Fabricio T Romagnol ◽  
Sérgio Cavalheiro ◽  
Marcelo de Toledo Petrilli ◽  
...  

This case report describes the outcomes of tropomyosin receptor kinase (TRK) inhibitor treatment in an infant with an infantile fibrosarcoma (IFS) with a TPM3–NTRK1 gene fusion. The IFS on the left foot was refractory to chemotherapy and was partially resected. After 5 months, there was local recurrence and further surgery was performed. The patient developed pulmonary and central nervous system metastases. Pan-TRK antibody staining was positive and genomic profiling with next-generation sequencing confirmed a TPM3–NTRK1 gene fusion. The patient started treatment with larotrectinib in February 2019, with a durable response, including a clear reduction in brain metastases. Research on novel gene fusions and molecular testing to direct the use of targeted therapy should be encouraged, especially in refractory solid tumors.


Author(s):  
Gorkem Ugurlu ◽  
Mustafa Ugurlu ◽  
Meltem Kilic ◽  
Zuhal Apaydin ◽  
Ali Caykoylu

Sign in / Sign up

Export Citation Format

Share Document